{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:40Z","timestamp":1791229480137,"version":"4.1.0"},"reference-count":20,"publisher":"Impact Journals, LLC","issue":"46","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,10,6]]},"DOI":"10.18632\/oncotarget.20849","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T22:50:27Z","timestamp":1505256627000},"page":"80934-80940","source":"Crossref","is-referenced-by-count":12,"title":["Prediction of thyroidal 131I effective half-life in patients with Graves' disease"],"prefix":"10.18632","volume":"8","author":[{"given":"Ruiguo","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaowei","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Cooper","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 Disease","volume":"375","author":"Hegedus","year":"2016","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMct1007101","article-title":"Radioiodine therapy for hyperthyroidism","volume":"364","author":"Ross","year":"2011","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"S486","DOI":"10.1007\/s00259-002-0868-4","article-title":"Radioiodine therapy and thyrostatic drugs and iodine","volume":"29","author":"Schicha","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5","doi-asserted-by":"crossref","first-page":"S453","DOI":"10.1007\/s00259-002-0831-4","article-title":"Strategies of radioiodine therapy for Graves\u2019 disease","volume":"29","author":"Lind","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00259-007-0419-0","article-title":"Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design or science?","volume":"34","author":"Gross","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of radioiodine doses in Graves\u2019 hyperthyroidism","volume":"88","author":"Cowden","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"8","doi-asserted-by":"crossref","first-page":"022502","DOI":"10.1118\/1.4788660","article-title":"Determining thyroid (131)I effective half-life for the treatment planning of Graves\u2019 disease","volume":"40","author":"Buchpiguel","year":"2013","journal-title":"Med Phys"},{"key":"9","doi-asserted-by":"crossref","first-page":"e6035","DOI":"10.1097\/MD.0000000000006035","article-title":"Risk factors of hepatic dysfunction in patients with Graves\u2019 hyperthyroidism and the efficacy of 131iodine treatment","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/thy.2000.10.779","article-title":"Accuracy considerations when using early (four- or six-hour) radioactive iodine uptake to predict twenty-four-hour values for radioactive iodine dosage in the treatment of Graves\u2019 disease","volume":"10","author":"Braunstein","year":"2000","journal-title":"Thyroid"},{"key":"11","first-page":"2","article-title":"The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves\u2019 disease","volume":"13","author":"Broekhuizen-de Gast","year":"2010","journal-title":"Hell J Nucl Med"},{"key":"12","first-page":"1815","article-title":"Four- to twenty-four-hour uptake ratio: an index of rapid iodine-131 turnover in hyperthyroidism","volume":"37","author":"Kirchner","year":"1996","journal-title":"J Nucl Med"},{"key":"13","first-page":"228","article-title":"Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements","volume":"37","author":"Fink","year":"1996","journal-title":"J Nucl Med"},{"key":"14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MNM.0b013e328333d303","article-title":"Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?","volume":"31","author":"Schicha","year":"2010","journal-title":"Nucl Med Commun"},{"key":"15","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1002\/mp.12161","article-title":"Technical Note: Determination of individual thyroid clearance effective half-life with a common handheld electronic dosimeter","volume":"44","author":"Klaeser","year":"2017","journal-title":"Med Phys"},{"key":"16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","article-title":"High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover","volume":"38","author":"de Keizer","year":"2013","journal-title":"Clin Nucl Med"},{"key":"17","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2967\/jnumed.110.080473","article-title":"Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease","volume":"51","author":"Muller","year":"2010","journal-title":"J Nucl Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s00259-006-0234-z","article-title":"Change in the intrathyroidal kinetics of radioiodine under continued and discontinued antithyroid medication in Graves\u2019 disease","volume":"34","author":"Schuemichen","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1507\/endocrj.K06-057","article-title":"Two-day thionamide withdrawal prior to radioiodine uptake sufficiently increases uptake and does not exacerbate hyperthyroidism compared to 7-day withdrawal in Graves\u2019 disease","volume":"53","author":"Miyauchi","year":"2006","journal-title":"Endocr J"},{"key":"20","doi-asserted-by":"crossref","first-page":"F209","DOI":"10.1136\/fn.87.3.F209","article-title":"Ultrasound of the thyroid gland in the newborn: normative data","volume":"87","author":"Donaldson","year":"2002","journal-title":"Arch Dis Child Fetal Neonatal Ed"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20849","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T13:11:16Z","timestamp":1589202676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.20849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":20,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2017,10,6]]}},"alternative-id":["20849","29113356"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.20849","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]}}}